Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely terrible.

Work has begun in the UK on developing new tests that will spot if someone has “fat genes”. The project, which seeks to ...

Doctors are learning more about the wider effects of the injections, from lowering blood pressure to helping people quit ...

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk ...

Studies in neuroscience with applications to humans offer clues about what makes us start eating, and when we stop.

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or obesity, possibly delaying the need for knee replacements, Monash University-led research has found.

A new expert review endorses GLP-1 RAs and other medications for sustainable weight loss in children with obesity and MASLD.

Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or ...

The president of Omada Health talks about why decision makers need to be thinking about holistic weight-management care as ...

BUFFALO, N.Y. — In January, Nicole Albanese, PharmD, clinical associate professor of pharmacy practice in the University at ...